Updating survival estimates in patients with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) based on treatment-free interval length

Eric M. Ammann, Tait D. Shanafelt, Kara B. Wright, Bradley D. McDowell, Brian K. Link, Elizabeth A. Chrischilles

Research output: Contribution to journalArticle

2 Scopus citations

Abstract

We hypothesized that the length of treatment-free survival following (a) initial diagnosis and (b) first-line treatment would be associated with improved subsequent five-year relative survival (RS5) in patients with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL). 19,879 patients incident CLL/SLL cases (median age = 76 years) were identified from SEER-Medicare. RS5 improved from 0.73 (95% CI: 0.72, 0.74) at diagnosis to 0.81 (95% CI: 0.80, 0.82) at year 1 and 0.89 (95% CI: 0.83, 0.96) at year 10 among those who had not received treatment. In our analysis of survival patterns following first-line treatment, RS5 improved from 0.55 (95% CI: 0.53, 0.57) at initiation of first-line treatment to 0.84 (95% CI: 0.75, 0.92) among patients who had not been retreated at year 5 following first-line therapy. Longer periods of treatment-free survival following initial diagnosis and first-line treatment were both predictive of meaningfully improved prognosis in CLL/SLL patients.

Original languageEnglish (US)
Pages (from-to)643-649
Number of pages7
JournalLeukemia and Lymphoma
Volume59
Issue number3
DOIs
StatePublished - Mar 4 2018

Keywords

  • B-cell
  • Leukemia
  • Medicare
  • chronic
  • epidemiology
  • lymphocytic
  • lymphoma
  • non-Hodgkin
  • prognosis
  • survival

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Updating survival estimates in patients with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) based on treatment-free interval length'. Together they form a unique fingerprint.

  • Cite this